Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

Researchers in 2024 made unique and important discoveries that promise to help individuals suffering from addiction and their ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

serotonin–norepinephrine reuptake inhibitors, noradrenergic and specific serotonin receptor antagonists, dopamine and norepinephrine reuptake inhibitors, along with newly introduced ...

Selective serotonin reuptake inhibitors, or SSRIs, were the third class or generation of antidepressants developed. They are now the most commonly prescribed antidepressant medications. They are ...

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...

After hours: December 27 at 6:11:22 PM EST Loading Chart for NLSP ...

After hours: December 27 at 6:54:28 PM EST Loading Chart for AXSM ...

Objective: To compare the 24-hour sustained efficacy and safety of a new tramadol once-daily formulation (tramadol OAD) using Contramid ® controlled-release technology with a marketed twice-daily ...

It is the first and only oral NMDA receptor antagonist to be approved ... has US rights to Jazz Pharma's dual-acting dopamine and norepinephrine reuptake inhibitor Sunosi (solriamfetol), used ...

Nov. 12, 2024 — Obesity causes insulin resistance by increasing activation of the sympathetic nervous system and the release of the stress hormone norepinephrine, according to a new ...